Pfizer Inc Q1 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Maybe first on danuglipron on the upcoming data. Could you just walk us through what the key efficacy and safety thresholds you're looking to meet to move this forward. And sort of with regards to those thresholds, how you think about them in light of that, this is BID dosing? And how does that potentially impact the sort of commercial opportunity. And then just second, a quick one on your DMD Phase 3 CIFFREO trial. You previously guided to completion of recruitment in April of this year. Just could you give us a quick update here, and then how you view the opportunity and positioning in light of the fact that there's a potential competitor approval at the end of this month?

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions on the RSV vaccine, please. Firstly, on the older adult vaccine. On Slide 22, you note emerging mid-second season data supporting durable efficacy. I wonder if you can elaborate a little more here on patent you have in hand today, and you want to act to get that second-season data in front of the FDA approval. And assuming you do see protection into that second season, how might that imply your pricing in the U.S.? And then secondly, on the maternal vaccine, you have had launch schedule in Q4 on Slide 6 and it implies that, that may not happen until the first quarter of next year. So could you just provide more clarity on when you could launch a maternal vaccine.